Journal article

Feasibility of once weekly exenatide-LAR and enhanced diabetes care in Indigenous Australians with type 2 diabetes (Long-acting-Once-Weekly-Exenatide laR-SUGAR, 'Lower SUGAR' study)

Elif Ekinci, Felicity Pyrlis, Mariam Hachem, Louise J Maple-Brown, Alex Brown, Graeme Maguire, Leonid Churilov, Neale Cohen

INTERNAL MEDICINE JOURNAL | WILEY | Published : 2021

Abstract

BACKGROUND: Diabetes is 3-4 times more prevalent in Indigenous Australians with blood glucose levels often above target range. Once weekly formulations of exenatide(exenatide-LAR) have demonstrated significantly greater improvements in glycaemic management with no increased risk of hypoglycaemia and with reductions in bodyweight but have not been studied in Indigenous Australians. AIMS: To assess the feasibility and metabolic effects of once weekly supervised injection of exenatide-LAR in addition to standard care in Indigenous Australians with type 2 diabetes. METHODS: Two communities in Central Australia with longstanding specialist clinical outreach services were allocated by random coin ..

View full abstract

Grants

Awarded by NHMRC Early Career Fellowship


Awarded by NHMRC Practitioner Fellowship


Awarded by NHMRC Fellowship


Funding Acknowledgements

This project was supported by research grant funding from AstraZeneca who funded the study medication and the study coordinator staff. AstraZeneca did not have input into study design or interpretation of the results. E. I. Ekinci was supported by a NHMRC Early Career Fellowship (#1054312), a Sir Edward Weary Dunlop Medical Research Foundation research grant, Diabetes Australia Research Program Grant, Viertel Clinical Investigatorship and a RACP Fellowship. L. J. Maple-Brown was supported by a NHMRC Practitioner Fellowship (#1078477). A. Brown was supported by a NHMRC Fellowship (#1137563).